Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6
Yonghao Qi1, Ambara R Pradipta2, Miao Li1
1Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, Nankai District, 300072, People's Republic of China.
Background:
Cancer cells are known to over-express TRAF6 that is critical for both AKT and TAK1 activations. The Really Interesting New Gene (RING) domain of TRAF6 is believed to be responsible for the E3 ligase activity, ZINC fingers of TRAF6 provide critical support for the activity of the RING domain which is critical for both AKT and TAK1 activations.
Methods:
We employed computational docking program to identify small molecules that could effectively and competitively bind with the RING domain of TRAF6, which is believed to be responsible for its E3 ligase activity. MTT assay and flow cytometry were employed to analyze apoptosis of cancer cells. Signaling pathways were detected using immunoprecipitation and western blotting, and immunofluorescence was pursued to assess the nature of binding of cinchonine to TRAF6. We also performed animal experiments to test effect of cinchonine in vivo.
Results:
Cinchonine, a naturally occurring Cinchona alkaloid identified from the docking study, could bind to TRAF6 in HeLa and A549 cells and induce apoptosis of these cancer cells. We found that AKT ubiquitination and phosphorylation as well as phosphorylation of TAK1 were decreased. These activities would lead to subsequent suppression anti-apoptotic protein Bcl-2, while elevating pro-apoptotic protein Bax. Immunofluorescence staining unambiguously demonstrated the binding of cinchonine specifically at the RING domain of TRAF6 in cells, thereby validating the computational modeling. Animal experiments showed that cinchonine could suppress tumor growth in mice without showing significant acute toxicity.
Conclusion:
These investigations suggest that through competitive binding with the RING domain of TRAF6, cinchonine could induce apoptosis via inhibiting AKT and TAK1 signaling pathways.
Insights
Cinchonine, a natural compound, targets the TRAF6 protein
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Tumorigenesis involves the overexpression of TRAF6, a key regulator of AKT and TAK1 signaling pathways.
- The Really Interesting New Gene (RING) domain of TRAF6 is essential for its E3 ligase activity, crucial for cancer cell proliferation.
- TRAF6's zinc fingers support the RING domain's function in activating AKT and TAK1.
Purpose of the Study:
- To identify small molecules that inhibit TRAF6's E3 ligase activity by targeting its RING domain.
- To investigate the anti-cancer effects of cinchonine, a Cinchona alkaloid, on cancer cells and in vivo tumor models.
Main Methods:
- Computational docking was used to screen for TRAF6-binding small molecules.
- MTT assays and flow cytometry assessed cancer cell apoptosis.
- Western blotting, immunoprecipitation, and immunofluorescence analyzed signaling pathways and drug-target interactions.
- In vivo animal experiments evaluated cinchonine's anti-tumor efficacy and toxicity.
Main Results:
- Cinchonine was identified as a TRAF6 inhibitor that binds to its RING domain in HeLa and A549 cells, inducing apoptosis.
- Cinchonine treatment decreased AKT ubiquitination and phosphorylation, and TAK1 phosphorylation, leading to reduced Bcl-2 and increased Bax levels.
- Immunofluorescence confirmed cinchonine's specific binding to the TRAF6 RING domain.
- Animal studies demonstrated cinchonine's tumor growth suppression in mice with minimal acute toxicity.
Conclusions:
- Cinchonine induces cancer cell apoptosis by competitively binding to the TRAF6 RING domain.
- This mechanism inhibits AKT and TAK1 signaling pathways, offering a potential therapeutic strategy for cancer treatment.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
MAPK Signaling Cascades
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity


